| Dr Renee L Micielli, MD | |
|
11245 Huron St, Westminster, CO 80234-2806 | |
| (303) 338-4545 | |
| Not Available |
| Full Name | Dr Renee L Micielli |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 20 Years |
| Location | 11245 Huron St, Westminster, Colorado |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134248545 | NPI | - | NPPES |
| 32303882 | Medicaid | CO | |
| 021044 | Other | CO | KAISER COMMERCIAL NUMBER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 49195 (Colorado) | Primary |
| 390200000X | Student In An Organized Health Care Education/training Program | 4301084127 (Michigan) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Colorado Permanente Medical Group Pc | 1254238454 | 1113 |
News Archive
The advantages of prescribing angiotensin-converting enzyme (ACE) inhibitors for stable coronary artery disease (CAD) may be increased by targeting the therapy to the patients most likely to benefit.Clinical characteristics alone do not allow a reliable identification of these patients, so a research programme was carried out at Erasmus University Medical Centre in Rotterdam to develop a genetic profiling model that predicts the treatment benefits of ACE inhibitors and optimises the recommended therapy.
Scottish scientists have shed light on the connection between deprivation and breast cancer survival, confirming that the link is mirrored at a genetic level.
Merck & Co., Inc. today said it will vigorously appeal a Massachusetts federal court jury verdict concerning allegations that a former subsidiary of Schering-Plough Corporation, Warrick Pharmaceuticals, caused the Commonwealth of Massachusetts to overpay local pharmacists for prescriptions of albuterol. Merck and Schering-Plough merged in November 2009. Warrick ceased operations prior to the merger, in 2008.
The HealthPartners Research Foundation has received an US Department of Health & Human Services Agency for Healthcare Research and Quality grant to study the transformation of traditional primary care clinics in Minnesota to "health care homes," also known as "medical homes."
The US Food and Drugs Administration (FDA) has approved Byetta (exenatide) injection as add-on treatment for use with insulin glargine, together with exercise and diet for diabetes type 2 patients who are not responding well enough to glargine alone. Byetta's add-on therapy is for those on glargine with metformin and/or a TZD (thiazolidinedione) or without.
› Verified 5 days ago
| Entity Name | Colorado Permanente Medical Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760599724 PECOS PAC ID: 1254238454 Enrollment ID: O20031216000640 |
News Archive
The advantages of prescribing angiotensin-converting enzyme (ACE) inhibitors for stable coronary artery disease (CAD) may be increased by targeting the therapy to the patients most likely to benefit.Clinical characteristics alone do not allow a reliable identification of these patients, so a research programme was carried out at Erasmus University Medical Centre in Rotterdam to develop a genetic profiling model that predicts the treatment benefits of ACE inhibitors and optimises the recommended therapy.
Scottish scientists have shed light on the connection between deprivation and breast cancer survival, confirming that the link is mirrored at a genetic level.
Merck & Co., Inc. today said it will vigorously appeal a Massachusetts federal court jury verdict concerning allegations that a former subsidiary of Schering-Plough Corporation, Warrick Pharmaceuticals, caused the Commonwealth of Massachusetts to overpay local pharmacists for prescriptions of albuterol. Merck and Schering-Plough merged in November 2009. Warrick ceased operations prior to the merger, in 2008.
The HealthPartners Research Foundation has received an US Department of Health & Human Services Agency for Healthcare Research and Quality grant to study the transformation of traditional primary care clinics in Minnesota to "health care homes," also known as "medical homes."
The US Food and Drugs Administration (FDA) has approved Byetta (exenatide) injection as add-on treatment for use with insulin glargine, together with exercise and diet for diabetes type 2 patients who are not responding well enough to glargine alone. Byetta's add-on therapy is for those on glargine with metformin and/or a TZD (thiazolidinedione) or without.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Renee L Micielli, MD 10350 E Dakota Ave, Denver, CO 80247-1314 Ph: () - | Dr Renee L Micielli, MD 11245 Huron St, Westminster, CO 80234-2806 Ph: (303) 338-4545 |
News Archive
The advantages of prescribing angiotensin-converting enzyme (ACE) inhibitors for stable coronary artery disease (CAD) may be increased by targeting the therapy to the patients most likely to benefit.Clinical characteristics alone do not allow a reliable identification of these patients, so a research programme was carried out at Erasmus University Medical Centre in Rotterdam to develop a genetic profiling model that predicts the treatment benefits of ACE inhibitors and optimises the recommended therapy.
Scottish scientists have shed light on the connection between deprivation and breast cancer survival, confirming that the link is mirrored at a genetic level.
Merck & Co., Inc. today said it will vigorously appeal a Massachusetts federal court jury verdict concerning allegations that a former subsidiary of Schering-Plough Corporation, Warrick Pharmaceuticals, caused the Commonwealth of Massachusetts to overpay local pharmacists for prescriptions of albuterol. Merck and Schering-Plough merged in November 2009. Warrick ceased operations prior to the merger, in 2008.
The HealthPartners Research Foundation has received an US Department of Health & Human Services Agency for Healthcare Research and Quality grant to study the transformation of traditional primary care clinics in Minnesota to "health care homes," also known as "medical homes."
The US Food and Drugs Administration (FDA) has approved Byetta (exenatide) injection as add-on treatment for use with insulin glargine, together with exercise and diet for diabetes type 2 patients who are not responding well enough to glargine alone. Byetta's add-on therapy is for those on glargine with metformin and/or a TZD (thiazolidinedione) or without.
› Verified 5 days ago
Dr. Jonathan B Ramharack, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 14300 Orchard Pkwy, Westminster, CO 80023 Phone: 720-627-3761 | |
Dr. Rajesh K Sharma, M.D.,F.A.C.C. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 905 W 124th Ave Ste 150, Westminster, CO 80234 Phone: 720-772-8040 Fax: 720-805-1551 | |
Mark W Ptaskiewicz, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 7701 Sheridan Blvd, Westminster, CO 80003 Phone: 303-338-4545 | |
Dr. James M Martau, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 500 W 144th Ave Ste 140, Westminster, CO 80023 Phone: 303-430-2640 Fax: 303-430-2625 | |
Dr. Rebecca L Agnew, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 7701 Sheridan Blvd, Westminster, CO 80003 Phone: 303-338-4545 | |
Dr. Jeanette Farnum, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 14300 Orchard Pkwy, Westminster, CO 80023 Phone: 720-627-4073 Fax: 720-627-3758 | |
Ingrid Chang, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 8410 Decatur St, Westminster, CO 80031 Phone: 303-430-7000 Fax: 303-430-1506 |